Extrahepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Neuroendocrine Carcinoma

Background Transarterial chemoembolization (TACE) is often utilized for patients with inoperable neuroendocrine carcinoma liver metastases. Often, metastatic disease is not limited to the liver. The impact of extrahepatic disease (EHD) on outcomes and response after TACE has not been described.